Provention Bio, Inc. reported raising $28.5 Million in an initial SEC Form D filing, from an offering of $30 Million

Company

Location

About

Provention Bio is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. At Provention Bio, we approach autoimmune disease differently than traditional pharma, with a clear focus on early interception. Before symptoms present, before irreversible damage is done to the bodies, minds, and lives of patients and families, and before it’s too late —this is where we operate. Our lead investigational product candidate is currently under review by the U.S. Food and Drug Administration (FDA) for the delay or prevention of clinical type 1 diabetes in at-risk individuals. Our pipeline includes additional clinical-stage product candidates for autoimmune diseases, including celiac disease and lupus. We have a vision to change the world by unleashing the full potential of lives otherwise burdened or cut short by autoimmune disease. It may seem daunting, but once we realize the potential of every moment we can protect—in every life we can change—the work we do at Provention Bio becomes more than just a job. It becomes a calling. Provention Bio is an Equal Opportunity Employer. We invite you to learn more at www.ProventionBio.com and connect by following us on LinkedIn and Twitter (@ProventionBio).